Table 5.

Multivariable competing risks regression model using subdistribution hazard ratios to compare the cumulative incidence of biochemical recurrence across morphology and respective PTEN loss indicators

Variable	SHR (95% CI)	P
Gleason 3	0.75 (0.40, 1.39)	0.35
Gleason 5	1.004 (0.99, 1.02)	0.62
Gleason 4 subpattern
Glomeruloid	0.27 (0.088, 0.80)	0.018
Cribriform	3.72 (1.75, 7.94)	0.001
Poorly formed	1.81 (0.69, 4.80)	0.23
Intraductal carcinoma	1.10 (0.30, 4.04)	0.89
Age	0.999 (0.96, 1.04)	0.95
Pre-operative PSA	1.002 (0.999, 1.006)	0.18
Lymph nodes removed	1.97 (0.96, 4.02)	0.063
Lymph nodes positive	1.95 (0.88, 4.34)	0.10
Positive margins	1.04 (0.57, 1.91)	0.89
Stage T2**	Ref.	Ref.
Stage T3a	2.99 (1.43, 6.25)	0.004
Stage T3b	7.32 (2.53, 21.2)	< 0.001
PTEN loss
Gleason 3	0.54 (0.25, 1.16)	0.11
Gleason 4 glomeruloid	4.07 (1.04, 15.9)	0.043
Gleason 4 cribriform	1.10 (0.50, 2.41)	0.81
Gleason 4 poorly formed	0.57 (0.21, 1.53)	0.26
Intraductal carcinoma	0.98 (0.24, 4.11)	0.98

CI, confidence interval; PTEN, phosphatase and tensin homologue; SHR, subdistribution hazard ratio.

Statistically significant P values are highlighted in bold.

^**Omnibus test of association between stage and cumulative incidence of biochemical recurrence: P < 0.001.